edaravone dexborneol

**Edaravone dexborneol** is a fixed-dose neuroprotective combination of the free-radical scavenger edaravone and dexborneol, the dextrorotatory form of borneol, supplied at a 4:1 edaravone:dexborneol ratio. It was developed by Simcere as Sanbexin and is marketed in China as an injectable concentrated solution and a sublingual tablet for improving neurological symptoms, activities of daily living, and functional impairment caused by acute ischemic stroke. The combination is designed to provide complementary antioxidant, anti-inflammatory, and blood-brain-barrier protective activity; the sublingual formulation enables rapid mucosal absorption while avoiding first-pass hepatic metabolism. ([simcere.com](https://www.simcere.com/en/pro/detail.aspx?mtt=63))

Brand names

SanbexinXianbixin

Other names

C.EDAEda.Bedaravone + dexborneoledaravone and (+)-borneoledaravone and dexborneoledaravone-dexborneolEDB依达拉奉右莰醇